BioSpace News Archive

Medtronic plc, a global leader in healthcare technology, announced long-term results from the SYMPLICITY HTN-3 clinical trial.

ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise™ Ultrasound Renal Denervation System as a treatment for hypertension.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has appointed Rogers Yongqing Luo as Chief Executive Officer of the Company, effective immediately.

Antengene Corporation Limited announced that ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.

Biohaven Pharmaceutical Holding Company Ltd. announced that it has set a record date of September 26, 2022 for the previously announced spin-off by Biohaven of its Biohaven Ltd. subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven.